The role of erythropoietin in myocardial protection: potential mechanisms and applications

References

• Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 293(1), 90–95 (2005).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc. Res. 59(3), 538–548 (2003).
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end stage renal disease with recombinant human erythropoietin. Results of a combined Phase I and II clinical trial. N. Engl. J. Med. 316(2), 73–78 (1987).
   PubMed Web of Science ®Google Scholar
• Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc. Natl Acad. Sci. USA 82(22), 7580–7584 (1985).
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37(7), 1775–1780 (2001).
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Blum M et al. The effect of correction of anemia in diabetics and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol. Dial. Transplant 18(1),141–146 (2003).
   PubMed Web of Science ®Google Scholar
• Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107(2), 294–299 (2003).
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Cereb. Blood Flow Metab. 22(5), 503–514 (2002).
   PubMedGoogle Scholar
• Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8(8), 495–505 (2002).
   Google Scholar
• George J, Patal S, Wexler D et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch. Intern. Med. 165(11), 1304–1309 (2005).
   PubMed Web of Science ®Google Scholar
• vanderMeer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J. Am. Coll. Cardiol. 44(1), 63–67 (2005).
   Google Scholar
• Namiuchi S, Kagaya Y, Ohta J et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 45(9), 1406–1412 (2005).
   PubMed Web of Science ®Google Scholar
• Moon C, Krawczyk M, Ahn D et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl Acad. Sci. USA 100(20), 11612–11617 (2003).
   PubMed Web of Science ®Google Scholar
• Porter DL, Goldberg MA. Physiology of erythropoietin production. Semin. Hematol. 31(2), 112–121 (1994).
   PubMedGoogle Scholar
• Eckardt KU, Koury ST, Tan CC et al. Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia. Kidney Int. 43(4), 815–823 (1993).
   PubMed Web of Science ®Google Scholar
• Dame C, Fahnenstich H, Freitag P et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 92(9), 3218–3225 (1998).
   PubMed Web of Science ®Google Scholar
• Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 269(30), 19488–19493 (1994).
   PubMed Web of Science ®Google Scholar
• Mulcahy L. The erythropoietin receptor. Semin. Oncol. 28(2), 19–23 (2001).
   PubMed Web of Science ®Google Scholar
• Lacombe C. Mayeux P. Biology of erythropoietin. Haematologica 83(8), 724–732 (1998).
   PubMed Web of Science ®Google Scholar
• Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl Acad. Sci. USA. 91(9), 3974–3978 (1994).
   PubMed Web of Science ®Google Scholar
• Tramontano AF, Muniyappa R, Black AD et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. 308(4), 990–994 (2003).
   PubMed Web of Science ®Google Scholar
• vanderMeer P, Lipsic E, Henning RH et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischaemia-reperfusion injury. Eur. J. Heart Fail. 6(7), 853–859 (2004).
   PubMedGoogle Scholar
• Cai Z, Manalo DJ, Wei G et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischaemia-reperfusion injury. Circulation 108(1), 79–85 (2003).
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Badiavas EV, Costa-Giomi P, Weinmann R, Erslev AJ, Caro J. Stimulation of erythropoietin gene transcription during hypoxia and cobalt exposure. Blood 73(1), 13–16 (1989).
   PubMed Web of Science ®Google Scholar
• Jelkmann W, Hellwig-Burgel T. Biology of erythropoietin. Adv. Exp. Med. Biol. 502, 169–187 (2001).
   PubMed Web of Science ®Google Scholar
• Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283(5404), 990–993 (1999).
   PubMed Web of Science ®Google Scholar
• Rafiee P, Shi Y, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Erythropoietin protects the infant heart against ischaemia-reperfusion injury by triggering multiple signaling pathways. Basic Res. Cardiol. 100(3), 187–197 (2005).
   PubMed Web of Science ®Google Scholar
• Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischaemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J. 19(10), 1323–1325 (2005).
   PubMed Web of Science ®Google Scholar
• Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischaemia/reperfusion injury. Circulation 109(17), 2050–2053 (2004).
   PubMed Web of Science ®Google Scholar
• Silva M, Benito A, Sanz C et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 274(32), 22165–22169 (1999).
   PubMed Web of Science ®Google Scholar
• Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul. Pharmacol. 42(5–6), 233–241 (2005).
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc. Med. 15(2), 69–75 (2005).
   PubMed Web of Science ®Google Scholar
• Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80(5), 729–738 (1995).
   PubMed Web of Science ®Google Scholar
• Verdier F, Walrafen P, Hubert N et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling downregulation of cell surface receptors. J. Biol. Chem. 275(24), 18375–18381 (2000).
   PubMed Web of Science ®Google Scholar
• Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126(16), 3597–3605 (1999).
   PubMed Web of Science ®Google Scholar
• Suzuki N, Ohneda O, Takahashi S et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 100(7), 2279–2288 (2002).
   PubMed Web of Science ®Google Scholar
• Wald MR, Borda ES, Sterin-Borda L. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J. Cell Physiol. 167(3), 461–468 (1996).
   PubMedGoogle Scholar
• Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium from ischaemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad. Sci. USA 100(8), 4802–4806 (2003).
   PubMed Web of Science ®Google Scholar
• Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted Heart J. Clin. Invest. 112(7), 999–1007 (2003).
   Google Scholar
• Parsa CJ, Kim J, Riel RU et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J. Biol. Chem. 279(20), 20655–20662 (2004).
   PubMed Web of Science ®Google Scholar
• Lipsic E, van der Meer P, Henning RH et al. Timing of erythropoietin treatment for cardioprotection in ischaemia/reperfusion. J. Cardiovasc. Pharmacol. 44(4), 473–479 (2004).
   PubMed Web of Science ®Google Scholar
• Shi Y, Rafiee P, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res. Cardiol. 99(3), 173–182 (2004).
   PubMed Web of Science ®Google Scholar
• Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 39(2), 259–265 (1991).
   PubMed Web of Science ®Google Scholar
• Morakkabati N, Gollnick F, Meyer R, Fandrey J, Jelkmann W. Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp. Hematol. 24(2), 392–397 (1996).
   PubMed Web of Science ®Google Scholar
• Sekiguchi N, Inoguchi T, Kobayashi K, Nawata H. Effect of erythropoietin on endothelial cell apoptosis induced by high glucose. Diabetes Res. Clin. Pract. 66(Suppl. 1), S103–S107 (2004).
   Google Scholar
• Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc. Natl Acad. Sci. USA 98(16), 9050–9055 (2001).
   PubMed Web of Science ®Google Scholar
• Yamaura G, Turoczi T, Yamamoto F, Siddqui MA, Maulik N, Das DK. STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 285(2), H476–H482 (2003).
   PubMed Web of Science ®Google Scholar
• Mascareno E, El-Shafei M, Maulik N et al. JAK/STAT signaling is associated with cardiac dysfunction during ischaemia and reperfusion. Circulation 104(3), 325–329 (2001).
   PubMed Web of Science ®Google Scholar
• Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res. Cardiol. 100(5), 397–403 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang J, Baines CP, Zong C et al. Functional proteomic analysis of a three-tier PKCepsilon-Akt-eNOS signaling module in cardiac protection. Am. J. Physiol. Heart Circ. Physiol. 288(2), H954–H961 (2005).
   PubMedGoogle Scholar
• Rui T, Feng Q, Lei M et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischaemia/reperfusion via induction of AP-1. Cardiovasc. Res. 65(3), 719–727 (2005).
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399(6736), 601–605 (1999).
   PubMed Web of Science ®Google Scholar
• Ito K, Sato T, Arita M. Protein kinase C isoform-dependent modulation of ATP-sensitive K+ channels during reoxygenation in guinea-pig ventricular myocytes. J Physiol. 532(Pt 1), 165–174 (2001).
   Google Scholar
• Xu W, Liu Y, Wang S et al. Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane. Science 298(5595), 1029–1033 (2002).
   PubMed Web of Science ®Google Scholar
• Cirillo M, Capasso G, DeSanto NG. Relationship between hematocrit and blood pressure: implications for primary hypertension. Nephron 65(4), 505–510 (1993).
   PubMedGoogle Scholar
• Akimoto T, Kusano E, Ito C et al. Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J. Hypertens. 19(2), 193–202 (2001).
   PubMedGoogle Scholar
• Gogusev J, Zhu DL, Herembert T, Ammarguellat F, Marche P, Drueke T. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 199(2), 977–983 (1994).
   PubMedGoogle Scholar
• Sabatine MS, Morrow DA, Giugliano RP et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111(16), 2042–2049 (2005).
   PubMed Web of Science ®Google Scholar
• Fiordaliso F, Chimenti S, Staszewsky L et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischaemia-reperfusion injury. Proc. Natl Acad. Sci. USA. 102(6), 2046–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Wagner KF, Katschinski DM, Hasegawa J et al. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97(2), 536–542 (2001).
   PubMed Web of Science ®Google Scholar
• Wexler D, Silverberg D, Blum M et al. Anemia as a contributor to morbidity and mortality in congestive heart failure. Nephrol. Dial. Transplant. 20(Suppl. 7), 11–15 (2005).
   Google Scholar
• Opasich C, Cazzola M, Scelsi L et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anemia in patients with chronic heart failure. Eur. Heart J. Jun 29 (Epub ahead of print) (2005).
   PubMedGoogle Scholar
• Silverberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 35(7), 1737–1744 (2000).
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107(2), 223–225 (2003).
   PubMed Web of Science ®Google Scholar
• Volpe M, Tritto C, Testa U et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am. J. Cardiol. 74(5), 468–473 (1994).
   PubMed Web of Science ®Google Scholar
• Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J. Card. Fail. 10(1 Suppl.), S5–S9 (2004).
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur. J. Heart Fail. 2(4), 393–398 (2000).
   PubMedGoogle Scholar
• Muller-Ehmsen J, Schmidt A, Krausgrill B, Schwinger RH, Bloch W. Role of Erythropoetin for Angiogenesis and Vasculogenesis - from Embryonic Development through Adulthood. Am. J. Physiol. Heart Circ. Physiol. Jul 15 (Epub ahead of print) (2005).
   PubMedGoogle Scholar
• George J, Goldstein E, Abashidze A et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc. Res. Jul 25 [Epub ahead of print] (2005).
   PubMedGoogle Scholar
• Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102(4), 1340–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, DeGroot K, Duckert T et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 64(5), 1648–1652 (2003).
   PubMed Web of Science ®Google Scholar
• Ribatti D, Presta M, Vacca A et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93(8), 2627–2636 (1999).
   PubMed Web of Science ®Google Scholar
• Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 47(3), 740–745 (1995).
   PubMed Web of Science ®Google Scholar
• Watanabe D, Suzuma K, Matsui S et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 353(8), 782–792 (2005).
   PubMed Web of Science ®Google Scholar
• Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 64(2), 326–333 (2002).
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Bohm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 26(4), 384–416 (2005).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97(3), 282–289 (1998).
   Google Scholar
• deBoer RA, van Veldhuisen DJ, van der Wijk J et al. Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. J. Card. Fail. 6(4), 330–337 (2000).
   PubMedGoogle Scholar
• Mitka M. Researchers probe anemia-heart failure link. JAMA. 290(14), 1835–1838 (2003).
   PubMedGoogle Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107(3), 363–369 (2003).
   PubMed Web of Science ®Google Scholar
• Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur. J. Heart Fail. 6(3), 355–358 (2004).
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Woodward M, Chalmers JP et al. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 45(1), 69–74 (2005).
   PubMedGoogle Scholar
• Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90(3), 297–303 (2004).
   PubMed Web of Science ®Google Scholar
• Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330(7492), 625 (2005).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Sullivan LM, Roubenoff R et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107(11), 1486–1491 (2003).
   PubMed Web of Science ®Google Scholar
• Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108(19), 2317–2322 (2003).
   PubMed Web of Science ®Google Scholar
• Yin WH, Chen JW, Jen HL et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am. Heart J. 147(5), 931–938 (2004).
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Woodward M, Chalmers JP et al. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 45(1), 69–74 (2005).
   PubMedGoogle Scholar
• Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur. J. Heart Fail. 4(3), 331–336 (2002).
   PubMedGoogle Scholar
• Tsutsui T, Tsutamoto T, Wada A et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J. Am. Coll. Cardiol. 39(6), 957–962 (2002).
   PubMed Web of Science ®Google Scholar
• George J, Wexler D, Roth A, Barak T, Sheps D. Keren G. Usefullness of anti-oxidized LDL antibody determination for assessment of clinical control in patients with heart failure. Eur. J. Heart Fail. (In Press) (2005).
   PubMedGoogle Scholar
• George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am. Heart J. (In Press) (2005).
   PubMedGoogle Scholar
• Iaccarino G, Barbato E, Cipolletta E et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur. Heart J. 26(17), 1752–1758 (2005).
   PubMed Web of Science ®Google Scholar
• Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischaemia-reperfusion injury. FASEB J. 18(9), 1031–1033 (2004).
   PubMed Web of Science ®Google Scholar
• Kertesz N, Wu J, Chen TH, Sucov HM, Wu H. The role of erythropoietin in regulating angiogenesis. Dev. Biol. 276(1), 101–110 (2004).
   PubMed Web of Science ®Google Scholar
• Hirata A, Minamino T, Asanuma H et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc. Drugs Ther. 19(1), 33–40 (2005).
   PubMed Web of Science ®Google Scholar
• Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischaemia-reperfusion injury. FASEB J. 18(9), 1031–1033 (2004).
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan R, Hallam K, Li Q, Ramasamy R. JAK-STAT pathway in cardiac ischemic stress. Vascul. Pharmacol. (Epub ahead of print) (2005).
   PubMedGoogle Scholar
• Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. FASEB J. May 19(7), 795–797 (2005).
   PubMed Web of Science ®Google Scholar
• Hattori R, Maulik N, Otani H et al. Role of STAT3 in ischemic preconditioning. J. Mol. Cell Cardiol. 33(11), 1929–1936 (2001).
   PubMed Web of Science ®Google Scholar
• Hilfiker-Kleiner D, Hilfiker A, Fuchs M et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ. Res. 95(2), 187–195 (2004).
   PubMedGoogle Scholar
• Yoshikawa H, Powell WJ Jr, Bland JH, Lowenstein E. Effect of acute anemia on experimental myocardial ischaemia. Am. J. Cardiol. 32(5), 670–678 (1973).
   PubMedGoogle Scholar
• Zeidman A, Fradin Z, Blecher A, Oster HS, Avrahami Y, Mittelman M. Anemia as a risk factor for ischemic heart disease. Isr. Med. Assoc. J. 6(1), 16–18 (2004).
   PubMed Web of Science ®Google Scholar
• Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305(5681), 239–242 (2004).
   PubMed Web of Science ®Google Scholar
• Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor. Proc. Natl Acad. Sci. USA 101(41), 14907–14912 (2004).
   PubMed Web of Science ®Google Scholar
• Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: hematologic management. Ann. Intern. Med. 109(5), 406–413 (1988).
   PubMed Web of Science ®Google Scholar
• Bassenge E, Munzel T. Consideration of conduit and resistance vessels in regulation of blood flow. Am. J. Cardiol. 62(8), 40–44 (1988).
   Google Scholar
• Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl Acad. Sci. USA 87(15), 5978–5982 (1990).
   PubMed Web of Science ®Google Scholar
• Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am. J. Pathol. 163(3), 993–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J. Biol. Chem. 273(39), 25381–25387 (1998).
   PubMed Web of Science ®Google Scholar